TRY NOW

Enhance and accelerate your early stage research with trusted and comprehensive intelligence from Thomson Reuters.

Start your free trial in just two simple steps.

Get your FREE trial

Enrich your discovery science with market leading, manually curated scientific intelligence. Systems Biology, Preclinical, Biomarkers, Chemistry, Biology, and Pharmacology - and everything in between. Covered from the perspective that matters most – yours.
Customer Feedback
Customer Feedback

Annette Bakker, Chief Scientific Officer from CTF, explains the reasons why she likes to work with Thomson Reuters. Currently using MetaCore™ to identify disease treatment options.

Live & Recorded Training

Attend one of our regularly scheduled webinar training sessions for overviews of features, tools, and content – find the schedule here

Free Pathway Maps

Search or browse through a wide range of proprietary multi-step canonical pathway maps here.

Featured News

The latest news from Life Sciences Research
The future of COPD treatment

The future of COPD treatment

Our research shows greater focus on preventative therapies

Translational Medicine

Translational Medicine

Supplement-Size Doses of Antioxidants Hasten Lung Cancer Progression

Tet Proteins Erase Epigenetic Marks

Tet Proteins Erase Epigenetic Marks

It is (reasonably) common knowledge that DNA is written in a simple four-letter code: ACTG. Too simple, actually.

Blog Highlights

Read our latest blog posts

Thank you for your readership!

Thomson Reuters Life Sciences Connect has moved to a new location on our IP & Science website, and this site is no longer updated or ...

Superbugs and Superdrugs, Pushing Financial Incentives and Collaborative Incentives to Accelerate Clinical Success – SMi’s 18th Annual Conference, London, UK, March 16-17, 2016

Richard Bax (Transcrip Partners) introduced SMi’s 18th Annual Superbug and Superdrug Conference with an overview of where antibiotic development fits in the broader realm of ...

Gleevec: A Successful Life and Impact of Generics

The first oncology drug to be developed with rational drug design to target malignant cells, Novartis’ tyrosine kinase inhibitor (TKI) Gleevec (imatinib) has been hailed ...

Whitepapers & Publications

View our recent whitepapers and publications

Biomarkers: An indispensible addition to the drug development toolkit

In this white paper, Thomson Reuters explores the role of biomarkers as evaluative tools in improving clinical research and the ...

Systemic risk and bank consolidation: International evidence

http://dx.doi.org/10.1016/j.jbankfin.2013.11.032

Latest on Twitter

Latest on Linked In